These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18794123)

  • 1. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
    Meyer AN; McAndrew CW; Donoghue DJ
    Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
    Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
    Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
    Lievens PM; Liboi E
    J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCĪ³1/Src-mediated paxillin hyperphosphorylation.
    Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
    Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
    Meyer AN; Gastwirt RF; Schlaepfer DD; Donoghue DJ
    J Biol Chem; 2004 Jul; 279(27):28450-7. PubMed ID: 15105428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
    Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
    Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
    Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
    Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
    Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
    Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
    Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
    Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
    PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
    Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
    Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
    Bonaventure J; Horne WC; Baron R
    FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
    Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
    Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
    Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
    J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
    Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
    Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
    Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
    Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum.
    Lievens PM; Zanolli E; Garofalo S; Liboi E
    FEBS Lett; 2009 Oct; 583(19):3254-8. PubMed ID: 19761767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
    Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
    Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.